Edit

STADA Group

https://www.stada.com/

Last activity: 12.09.2024

Active

Categories: B2CExchangeHealthTechInformationInvestmentJobManufacturingMarketMedtechProduct

Die STADA Arzneimittel AG hat ihren Hauptsitz im hessischen Bad Vilbel. Das Unternehmen setzt auf eine Zwei-Säulen-Strategie bestehend aus Generika, inklusive Spezialpharmazeutika und verschreibungsfreien Consumer Health Produkten. Weltweit vertreibt die STADA Arzneimittel AG ihre Produkte in rund 120 Ländern.
Als verlässlicher Partner kümmern wir uns um die Gesundheit der Menschen. Unser Auftrag - Ihre Gesundheit

Likes

19.76K

Followers

38.42K

Website visits

76.5K /mo.

Mentions

Location: Germany, Hesse, Dortelweil

Employees: 10001+

Phone: +49 6101 6030

Founded date: 1992

Investors 2

Date	Name	Website
-	Cinven	cinven.com
-	Bain Capit...	baincapita...

Mentions in press and media 22

Date	Title	Description
16.09.2024	The Future of Finance: Partnerships and Leadership in a Changing Landscape	In the fast-paced world of finance, partnerships are the lifeblood of innovation. Companies are not just looking to survive; they aim to thrive. Recent developments from Genpact and STADA, as well as PrimeRevenue, illustrate this trend vivi...
12.09.2024	Genpact and STADA Renew Multi-Year Partnership to Enhance Finance Operations	Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE: G), a global professional services and solutions fi...
14.08.2024	Calliditas and Asahi Kasei: A Strategic Dance in the Biopharma Arena	In the fast-paced world of biopharmaceuticals, every move counts. Calliditas Therapeutics AB, a Swedish biopharma company, recently unveiled its interim report for the first half of 2024. The numbers tell a story of growth, challenges, and ...
13.08.2024	Calliditas Interim Report January to June 2024	Calliditas Interim Report January to June 2024 Tue, Aug 13, 2024 07:00 CET Report this content Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX): April to June 2024 (compared to April to June 2023) Net sales amounted to SEK...
27.07.2024	Calliditas Therapeutics: A Beacon of Hope in Rare Disease Treatment	In the ever-evolving landscape of biopharmaceuticals, Calliditas Therapeutics is making waves. The company recently announced significant advancements in two of its key treatments, setanaxib and Kinpeygo, which target rare diseases with sub...
26.07.2024	Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy	Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy Fri, Jul 26, 2024 17:00 CET Report this content Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: C...
18.07.2024	Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million	Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million Thu, Jul 18, 2024 07:45 CET Report this content NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATE...
30.05.2024	Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy	Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy Thu, May 30, 2024 20:00 CET Report this content Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockho...
23.05.2024	Calliditas Q1 report, January – March 2024	Calliditas Q1 report, January – March 2024 Thu, May 23, 2024 07:00 CET Report this content Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX): Target market expansion following full approval in the US JANUARY – MARCH 2024 (COMPARED TO JAN...
18.04.2024	Digital Health-Startup Kyan Health auf Wachstumskurs	Knapp 60 Prozent aller befragten Personen aus über 30 Ländern gaben letztes Jahr an, dass sie in den vergangenen 12 Monaten mindestens einmal wegen zu viel Stress der Arbeit fernblieben. Das zeigen Umfrageergebnisse des Forschungsinstituts...
03.04.2023	STADA and Xbrane launch ranibizumab to support patient access in Europe	Peter Goldschmidt, STADA CEO • Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane This European-made biosimilar, developed through STADA’s strategic partnership with Xbrane, will he...
06.03.2023	STADA sustains strong momentum with double-digit sales and profit growth in 2022	Peter Goldschmidt, STADA CEO • STADA sustains growth trajectory in 2022 with growth of 11% in sales and 17 % in EBITDA STADA was able in 2022 to sustain its strong growth journey of recent years. I am confident that STADA has the right pipe...
09.02.2023	EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)	Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) The EMA’s acceptance for filing marks a key milestone in making an additional treatment op...
11.01.2023	Adalvo and STADA extend their strategic partnership	STADA has extended its strategic partnership with Adalvo Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes Working closely as a trusted partner with Adalvo ...
02.01.2023	STADA appoints Boris Döbler as Chief Financial Officer	Boris Döbler, STADA CFO STADA appoints Döbler CFO • STADA’s VP Corporate Financial Planning & Analysis and former European Markets CFO Boris Döbler appointed as STADA’s Chief Financial Officer I am convinced that Boris’ expertise, dedic...
20.12.2022	STADA ranks among top 10% of pharma firms on sustainability	STADA ESG Summary Independent Sustainalytics ESG Risk Rating puts STADA among top 10% of pharma firms globally STADA’s commitment to sustainable development stems from the Group’s purpose of Caring for People’s Health as a Trusted Partner.”...
28.11.2022	STADA Starts Work on >EUR50m Facility to Strengthen European Medicines Supply	STADA CTO Miguel Pagan presents details of the planned facility STADA breaks ground on EUR50 mn+ investment in medicines supply-chain hub in Romania. Site expected to supply 100 million packs per year, creating 375 jobs Through this major i...
20.09.2022	STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease	Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A nephropathy (IgAN) Making this medicine available to primary IgAN patients in Europe brings for the first time a therapeuti...
11.07.2022	STADA Health Report 2022: Europe experiencing worsening health conditions	STADA Health Report 2022 reveals European healthcare trends STADA has published its STADA Health Report 2022 STADA Peter Goldschmidt launches the STADA Health Report 2022 (Source: Johannes Jost for Hubert Burda Media / STADA)) STADA Health ...
18.08.2021	DGAP-AFR : STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	DGAP Preliminary announcement financial reports: STADA Arzneimittel AG / Preliminary announcement on the disclosure of financial statements STADA Arzneimittel AG: Preliminary announcement of the publication of financial reports according to...
12.07.2021	Enzymatica and STADA extend agreement on ViruProtect to Vietnam	Enzymatica and STADA extend agreement on ViruProtect to Vietnam Mon, Jul 12, 2021 15:00 CET Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (ColdZyme®) in Vietnam. The agreement builds on the two companies’...
15.03.2017	PE consortia make binding $5b bid to takeover drugmaker Stada	Premium The two private equity consortia vying for Stada have made binding takeover offers each worth 4.7 billion euros ($5.0 billion) including debt, paving the way for a deeper look into the German generic drugmaker‘s books, several peopl...

STADA Group

Investors 2

Mentions in press and media 22

Reviews 0